EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudie

Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)

D Noviello, W Fries, A Orlando, F S Conforti, C Bezzio, F Castiglione, M C Fantini, E V Savarino, S Festa, D G Ribaldone, G Mocci, L Grossi und 24 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.04.025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von D Noviello und 35 weiteren Autor:innen. Beteiligte Einrichtung: University of Milan, Department of Pathophysiology and Transplantation, Milano, Italy. Hauptthemen laut MEDLINE: Piperidines, Colitis, Ulcerative, Pyrimidines, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, Pfizer, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Drug positioning in ulcerative colitis (UC) patients refractory to anti-tumor necrosis factor (TNF) is still debated. In a nationwide multicentre observational cohort, we aimed to compare the real-life effectiveness and safety of tofacitinib and vedolizumab as second-line for UC after anti-TNFs. METHODS: Disease activity was evaluated at weeks 8, 26, and 52 ± 4. The primary outcome was to compare clinical remission (partial Mayo score (PMS) ≤2 with no subscore >1) at week 26. Secondary outcomes included comparative effectiveness for corticosteroid-free clinical remission (CFCR); biochemical, endoscopic, and histologic remission; combined corticosteroid-free clinical-objective remission; and treatment persistence. Inverse probability of treatment weighting was used for all comparisons. RESULTS: Overall, 134 tofacitinib- and 277 vedolizumab-treated UC patients were included. At week 26, no difference was observed between tofacitinib and vedolizumab for clinical remission (adjusted odds ratio [aOR]: 0.9; 95 % confidence interval [CI]: 0.6 - 1.6). At week 8, tofacitinib was more effective in achieving CFCR (aOR: 1.7; 95 % CI: 1.0 - 2.7). Clinical, biochemical, endoscopic, and histologic outcomes showed no difference between tofacitinib and vedolizumab at weeks 26 and 52. In patients with baseline PMS ≥ 2, steroid use, or anti-TNF non-response no difference was found for clinical remission at week 26. Tofacitinib-treated patients were more likely to discontinue treatment (adjusted Hazard Ratio: 1.8; 95 % CI: 1.2 - 2.8). Safety was consistent with treatment profiles in UC. CONCLUSIONS: Tofacitinib and vedolizumab were equally effective and safe as second-line therapy in anti-TNFs experienced UC patients. Tofacitinib showed greater efficacy in inducing CFCR at week 8, but carried higher discontinuation risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesColitis, UlcerativePyrimidinesAntibodies, Monoclonal, HumanizedGastrointestinal AgentsPyrrolidinesProtein Kinase InhibitorsHumansMaleFemaleAdultMiddle AgedTreatment OutcomeRemission InductionTumor Necrosis Factor Inhibitors

Stichwörter der Autor:innen

EffectivenessReal word evidenceSafetyTofacitinibUlcerative colitisVedolizumab

Substanzen

tofacitinibvedolizumabPiperidinesPyrimidinesAntibodies, Monoclonal, HumanizedGastrointestinal AgentsPyrrolidinesTumor Necrosis Factor InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • University of Milan, Department of Pathophysiology and Transplantation, Milano, Italy.
  • University of Messina, Dept. of Clinical and Experimental Medicine, Messina, Italy.
  • "Villa Sofia-Cervello" Hospital, Inflammatory bowel disease Unit, Palermo, Italy.
  • Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milano, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy; IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
  • Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Naples, Italy.

Förderung

  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Pfizer
  • Ministero della Salute
  • AbbVie
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Zitieren

APA

Noviello, D., Fries, W., Orlando, A., Conforti, F. S., Bezzio, C., Castiglione, F., Fantini, M. C., Savarino, E. V., Festa, S., Ribaldone, D. G., Mocci, G., Grossi, L., Viganò, C., Imperatore, N., Ceccarelli, L., Gabrielli, A. M. C., Scardino, G., Saibeni, S., Balestrieri, P., …, & VE2TO-UC study group (2025). Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC). Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.04.025

Vancouver

Noviello D, Fries W, Orlando A, Conforti FS, Bezzio C, Castiglione F, et al. Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC). Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.04.025

BibTeX
@article{Noviello2025,
  author = {Noviello, D and Fries, W and Orlando, A and Conforti, F S and Bezzio, C and Castiglione, F and Fantini, M C and Savarino, E V and Festa, S and Ribaldone, D G and Mocci, G and Grossi, L and Viganò, C and Imperatore, N and Ceccarelli, L and Gabrielli, A M Carvalhas and Scardino, G and Saibeni, S and Balestrieri, P and Principi, M and Campigotto, M and Gravina, A G and Spagnuolo, R and Scaldaferri, F and Neri, B and Sario, A Di and Baldoni, M and Mitri, R Di and Tettoni, E and Calderone, S and Armuzzi, A and Macaluso, F S and Vecchi, M and Ventimiglia, M and Caprioli, F and VE2TO-UC study group, VE2TO-UC study group},
  title = {Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.04.025}
}
Kostenlos starten →